中国人群中CYP2D6基因rs1080985单核苷酸多态性及APOE多态性对阿尔茨海默病患者多奈哌齐治疗反应的影响
Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China.
作者信息
Liu Mengyuan, Zhang Ying, Huo Ya Ruth, Liu Shuling, Liu Shuai, Wang Junwei, Wang Change, Wang Jinhuan, Ji Yong
机构信息
Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China ; Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China ; Tianjin Neurosurgery Institute, Tianjin Huanhu Hospital, Tianjin, China.
Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China ; Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China.
出版信息
Dement Geriatr Cogn Dis Extra. 2014 Nov 15;4(3):450-6. doi: 10.1159/000367596. eCollection 2014 Sep.
BACKGROUND/AIM: Recent data have indicated that the rs1080985 single nucleotide polymorphism (SNP) of the cytochrome P450 (CYP) 2D6 and the common apolipoprotein E (APOE) gene may affect the response to donepezil in patients with Alzheimer's disease (AD). We investigated this association in Chinese patients with mild-to-moderate AD.
METHODS
In this prospective cohort study, analyses of CYP2D6 and APOE were conducted in 208 native Chinese patients with mild-to-moderate AD. All patients were treated with donepezil 5 mg/day for 6 months, and the response to treatment was assessed using the Mini-Mental State Examination.
RESULTS
No significant differences between responders (68.9%) and nonresponders (31.1%) to donepezil treatment (6 months' duration) were observed in the distribution of the CYP2D6 rs1080985 SNP, common APOE polymorphism or a combination of the two.
CONCLUSIONS
Our results suggest that neither the CYP2D6 nor the APOE polymorphism influences the 6-month response to donepezil treatment in a Chinese population with AD.
背景/目的：近期数据表明，细胞色素P450（CYP）2D6的rs1080985单核苷酸多态性（SNP）和常见的载脂蛋白E（APOE）基因可能影响阿尔茨海默病（AD）患者对多奈哌齐的反应。我们在中国轻至中度AD患者中研究了这种关联。
方法
在这项前瞻性队列研究中，对208名中国本土轻至中度AD患者进行了CYP2D6和APOE分析。所有患者均接受5毫克/天的多奈哌齐治疗6个月，并使用简易精神状态检查表评估治疗反应。
结果
在CYP2D6 rs1080985 SNP、常见APOE多态性或两者组合的分布中，未观察到对多奈哌齐治疗（6个月疗程）有反应者（68.9%）和无反应者（31.1%）之间存在显著差异。
结论
我们的结果表明，CYP2D6多态性和APOE多态性均不影响中国AD患者对多奈哌齐治疗6个月的反应。
Zotero 插件